Evidence map›Paper›PMID 38806475›Full record

ArticleBlood cancer journal2024

Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities.

Sikander Ailawadhi, Yaw Adu, Ryan D Frank, Saurav Das, David O Hodge, Andre Fernandez, Caitlyn Flott, Jamie Elliott, Ricardo Parrondo, Taimur Sher and 2 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Sikander AilawadhiDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA. ailawadhi.sikander@mayo.edu.ORCID 0000-0002-8377-8111
Yaw AduTexas Tech University Health Sciences Center School of Medicine, Lubbock, TX, USA.ORCID 0000-0003-2430-567X
Ryan D FrankDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
Saurav DasDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0003-0597-8123
David O HodgeDepartment of Health Sciences Research/Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA.
Andre FernandezDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
Caitlyn FlottDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
Jamie ElliottDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
Ricardo ParrondoDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-9314-9933
Taimur SherDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.
Vivek RoyDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-5950-4620
Asher A Chanan-KhanDivision of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
NCI NIH HHS P50 CA186781
6 · The paper itself

Abstract

Multiple myeloma (MM) therapeutics have evolved tremendously in recent years, with significant improvement in patient outcomes. As newer treatment options are developed, stem cell transplant (SCT) remains an important modality that provides excellent disease control and delays the progression of disease. Over the years, SCT use has increased overall in the U.S., but two distinct gaps remain, including suboptimal use overall and racial-ethnic disparities. We evaluated the National Cancer Database (NCDB) to study what sociodemographic factors might play a role within a given racial-ethnic group leading to disparate SCT utilization, such that targeted approaches can be developed to optimize SCT use for all. In nearly 112,000 cases belonging to mutually exclusive categories of non-Hispanic Whites (NHW), non-Hispanic Blacks (NHB), Hispanics, non-Hispanic Asians (NHA), and others, we found certain factors including age, comorbidity index, payor type, facility type (academic vs. community) and facility volume to be uniformly associated with SCT use for all the racial-ethnic groups, while gender was not significant for any of the groups. There were several other factors that had a differential impact on SCT utilization among the various race-ethnicity groups studied, including year of diagnosis (significant for NHW, NHB, and Hispanics), income level (significant for NHW and Hispanics), literacy level (significant for NHW and NHB), and geographic location of the treatment facility (significant for NHW and NHA). The suboptimal SCT utilization overall in the U.S. suggests that there may be room for improvement for all, even including the majority NHW, while we continue to work on factors that lead to disparities for the traditionally underserved populations. This study helps identify sociodemographic factors that may play a role specifically in each group and paves the way to devise targeted solutions such that resource utilization and impact can be maximized.

Indexed as

Healthcare DisparitiesMultiple MyelomaAdultAgedFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedStem Cell TransplantationUnited States

Identifiers

PMID38806475
PMCPMC11133435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.